Literature DB >> 15073535

Elevated erythropoietin in vitreous with ischemic retinal diseases.

Yasuya Inomata1, Akira Hirata, Eri Takahashi, Takahiro Kawaji, Mikiko Fukushima, Hidenobu Tanihara.   

Abstract

The aim of the current study was to measure the concentrations of erythropoietin in the vitreous fluid and analyze its association with vascular endothelial growth factor (VEGF) in ischemic vitreoretinal diseases. Vitreous fluid samples were collected from patients with proliferative diabetic retinopathy, branch retinal vein occlusion and idiopathic macular hole. Concentrations of erythropoietin and VEGF in vitreous fluid were significantly elevated in patients with proliferative diabetic retinopathy and branch retinal vein occlusion as compared to patients with macular hole. There were no differences in serum concentrations of erythropoietin and VEGF among patient groups. There was significant correlation between erythropoietin and VEGF concentrations in vitreous fluid. Erythropoietin was up-regulated in ischemic disorders and may act as an endogenous neuroprotective factor against ischemic retinal disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073535     DOI: 10.1097/00001756-200404090-00029

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  19 in total

Review 1.  The mouse retina as an angiogenesis model.

Authors:  Andreas Stahl; Kip M Connor; Przemyslaw Sapieha; Jing Chen; Roberta J Dennison; Nathan M Krah; Molly R Seaward; Keirnan L Willett; Christopher M Aderman; Karen I Guerin; Jing Hua; Chatarina Löfqvist; Ann Hellström; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06       Impact factor: 4.799

2.  Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes.

Authors:  Ahmed M Abu El-Asrar; Luc Missotten; Karel Geboes
Journal:  Br J Ophthalmol       Date:  2007-01-17       Impact factor: 4.638

3.  Endogenous erythropoietin protects neuroretinal function in ischemic retinopathy.

Authors:  Freya M Mowat; Francisco Gonzalez; Ulrich F O Luhmann; Clemens A Lange; Yanai Duran; Alexander J Smith; Patrick H Maxwell; Robin R Ali; James W B Bainbridge
Journal:  Am J Pathol       Date:  2012-02-17       Impact factor: 4.307

4.  Serum erythropoietin levels in patients with central serous chorioretinopathy.

Authors:  Burak Turgut; Nevin Ilhan; Fatma Yayla Uyar; Ulku Celiker; Tamer Demir; Suleyman Serdar Koca
Journal:  Eye Brain       Date:  2010-06-05

5.  Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy.

Authors:  Chuan Sun; Hongsong Zhang; Jingjing Jiang; Yuxin Li; Chuang Nie; Jianwen Gu; Ling Luo; Zhijun Wang
Journal:  Int Ophthalmol       Date:  2019-12-04       Impact factor: 2.031

6.  Neurodegeneration: An early event of diabetic retinopathy.

Authors:  Marta Villarroel; Andreea Ciudin; Cristina Hernández; Rafael Simó
Journal:  World J Diabetes       Date:  2010-05-15

7.  Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment.

Authors:  Sirpa Loukovaara; Kaisa Lehti; Alexandra Robciuc; Timo Pessi; Juha M Holopainen; Katri Koli; Ilkka Immonen; Jorma Keski-Oja
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-11-12       Impact factor: 3.117

Review 8.  The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier--implications for the pathogenesis of diabetic retinopathy.

Authors:  Rafael Simó; Marta Villarroel; Lídia Corraliza; Cristina Hernández; Marta Garcia-Ramírez
Journal:  J Biomed Biotechnol       Date:  2010-02-17

9.  Aqueous levels of erythropoietin in acute retinal vein occlusion with macular edema.

Authors:  Hyun Jin Shin; Hyung Chan Kim; Jun Woong Moon
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

10.  Diabetic retinopathy is not associated with carbonic anhydrase gene polymorphisms.

Authors:  S Abhary; K P Burdon; A Gupta; N Petrovsky; J E Craig
Journal:  Mol Vis       Date:  2009-06-13       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.